These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Creating the next generation of protein therapeutics through rational drug design. Szymkowski DE Curr Opin Drug Discov Devel; 2005 Sep; 8(5):590-600. PubMed ID: 16159021 [TBL] [Abstract][Full Text] [Related]
24. Strategies to improve oral drug bioavailability. Gomez-Orellana I Expert Opin Drug Deliv; 2005 May; 2(3):419-33. PubMed ID: 16296764 [TBL] [Abstract][Full Text] [Related]
25. Human antibodies from transgenic animals. Lonberg N Nat Biotechnol; 2005 Sep; 23(9):1117-25. PubMed ID: 16151405 [TBL] [Abstract][Full Text] [Related]
26. Drug research: from the idea to the product. Kuhlmann J Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711 [TBL] [Abstract][Full Text] [Related]
27. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models. Lowe PJ; Tannenbaum S; Wu K; Lloyd P; Sims J Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):195-209. PubMed ID: 20050847 [TBL] [Abstract][Full Text] [Related]
29. Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study. Eifler AC; Thaxton CS Methods Mol Biol; 2011; 726():325-38. PubMed ID: 21424459 [TBL] [Abstract][Full Text] [Related]
30. Pharmacological significance of glycosylation in therapeutic proteins. Li H; d'Anjou M Curr Opin Biotechnol; 2009 Dec; 20(6):678-84. PubMed ID: 19892545 [TBL] [Abstract][Full Text] [Related]
31. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. Koren E; Smith HW; Shores E; Shankar G; Finco-Kent D; Rup B; Barrett YC; Devanarayan V; Gorovits B; Gupta S; Parish T; Quarmby V; Moxness M; Swanson SJ; Taniguchi G; Zuckerman LA; Stebbins CC; Mire-Sluis A J Immunol Methods; 2008 Apr; 333(1-2):1-9. PubMed ID: 18275969 [TBL] [Abstract][Full Text] [Related]
32. Translational strategies for development of monoclonal antibodies from discovery to the clinic. Tabrizi MA; Bornstein GG; Klakamp SL; Drake A; Knight R; Roskos L Drug Discov Today; 2009 Mar; 14(5-6):298-305. PubMed ID: 19152840 [TBL] [Abstract][Full Text] [Related]
34. Analysis of clinical trials with biologics using dose-time-response models. Lange MR; Schmidli H Stat Med; 2015 Sep; 34(22):3017-28. PubMed ID: 26059422 [TBL] [Abstract][Full Text] [Related]
35. Therapeutic strategies for rheumatoid arthritis. Smolen JS; Steiner G Nat Rev Drug Discov; 2003 Jun; 2(6):473-88. PubMed ID: 12776222 [TBL] [Abstract][Full Text] [Related]
36. Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins. van Beers MM; Bardor M Biotechnol J; 2012 Dec; 7(12):1473-84. PubMed ID: 23027660 [TBL] [Abstract][Full Text] [Related]
37. The application of ICH S6 to the preclinical safety evaluation of plasma derivative therapeutic products. Lewis RM; Cavagnaro J Biologicals; 2010 Jul; 38(4):494-500. PubMed ID: 20359910 [TBL] [Abstract][Full Text] [Related]
38. Immunostimulatory antibodies: challenging the drug testing paradigm. Bhogal N; Combes R Toxicol In Vitro; 2007 Oct; 21(7):1227-32. PubMed ID: 17434714 [TBL] [Abstract][Full Text] [Related]
39. Aqueous two-phase systems: A viable platform in the manufacturing of biopharmaceuticals. Rosa PA; Ferreira IF; Azevedo AM; Aires-Barros MR J Chromatogr A; 2010 Apr; 1217(16):2296-305. PubMed ID: 19962707 [TBL] [Abstract][Full Text] [Related]